Introduction Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. Bristol Myers Squibb focuses on areas such as oncology, cardiovascular, immunoscience, and fibrosis to develop therapies that address significant unmet medical needs. The company's research and development efforts are centered around discovering new drugs and advancing existing ones to improve patient outcomes. |
Disease Domain | Count |
---|---|
Neoplasms | 257 |
Immune System Diseases | 126 |
Hemic and Lymphatic Diseases | 111 |
Nervous System Diseases | 89 |
Endocrinology and Metabolic Disease | 82 |
Infectious Diseases | 54 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 224 |
Monoclonal antibody | 51 |
Degradable Molecular Glue | 11 |
Autologous CAR-T | 10 |
Therapeutic radiopharmaceuticals | 10 |
Target |
Mechanism PD-1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date27 Dec 2024 |
Mechanism M1 receptor agonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date26 Sep 2024 |
Target |
Mechanism IDH1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Canada |
First Approval Date01 Aug 2024 |
Start Date24 Nov 2025 |
Sponsor / Collaborator |
Start Date02 Aug 2025 |
Sponsor / Collaborator |
Start Date31 Jul 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Aztreonam ( PBPs ) | Intraabdominal Infections More | Approved |
Deucravacitinib ( TYK2 ) | Plaque psoriasis More | Approved |
Dexamethasone ( GR ) | Multiple Myeloma More | Approved |
Repotrectinib ( ROS1 x TrkA x TrkB x TrkC ) | NTRK fusion-positive solid tumors More | Approved |
Pravastatin Sodium ( HMGCR ) | Dyslipidemias More | Approved |